IMNM
Immunome·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 3
Consensus Rating "Strong Buy"
MACD Golden Cross
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
EPS Beats Expectation
Bearish Abandoned Baby
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IMNM
Immunome, Inc.
A biopharmaceutical company that develops antibody therapeutics for the treatment of cancer and infectious diseases
18702 N. Creek Parkway, Suite 100 Bothell, WA 98011
--
Immunome, Inc., was incorporated as a Pennsylvania corporation on March 2, 2006 and converted to a Delaware corporation on December 2, 2015. The Company is a biopharmaceutical company that utilizes its proprietary Human Memory B Cell Platform to discover and develop first-in-class antibody therapies designed to transform the way diseases are currently treated. The company's patent discovery platform identifies new therapeutic antibodies and their targets from patients who have learned to beat the disease by leveraging a highly educated component of the immune system, memory B cells.
Company Financials
EPS
IMNM has released its 2025 Q3 earnings. EPS was reported at -0.65, versus the expected -0.54, missing expectations. The chart below visualizes how IMNM has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
